TG Therapeutics Announces Presentation of Exploratory
NEW YORK, Oct. 26, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced presentations highlighting exploratory analyses from...
Stay updated with breaking news from Bruceac Cree. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
NEW YORK, Oct. 26, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced presentations highlighting exploratory analyses from...
NEW YORK, June 27, 2022 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced data presentations highlighting data from pooled and post hoc analyses of the ULTIMATE I &
COVID rates after vaccination are relatively low and cases mild in patients with multiple sclerosis treated with disease-modifying therapies – but vaccine antibody response is lower with anti-CD20 therapies.
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the American Academy of Neurology Annual Meeting - read this article along with other careers information, tips and advice on BioSpace
Spinal atrophy observed on MRI correlates with progression to secondary progressive MS when other signs may not be evident, new research shows.